...
【24h】

Pediatric cardiac arrest refractory to advanced life support: is there a role for terlipressin?

机译:小儿心脏骤停难以维持晚期生命:特利加压素有作用吗?

获取原文
获取原文并翻译 | 示例

摘要

OBJECTIVE: Pediatric cardiac arrest unresponsive to advanced life support and several adrenaline doses has a very poor prognosis. Alternative vasopressors could improve the results of resuscitation in such cases. We report our experience with the compassionate administration of terlipressin in children who suffered in-pediatric intensive care unit cardiac arrest and did not respond to immediate advanced life support and at least three epinephrine doses. DESIGN: Prospective multicenter registry. SETTING: Three pediatric intensive care units at university-affiliated tertiary care children's hospitals. PATIENTS: Five pediatric patients, aged 5 mos to 12 yrs, with in-pediatric intensive care unit cardiac arrest unresponsive to advanced life support that included at least three epinephrine doses. INTERVENTIONS: Addition of terlipressin (10-20 microg/kg intravenous, up to two doses) to standard cardiopulmonary resuscitation. MEASUREMENTS AND MAIN RESULTS: Sustained return of spontaneous circulation was achieved in four cases, two of them were declared dead 6 and 12 hrs later, and the remaining two survived without cardiopulmonary procedures-related sequelae and with good neurologic condition. CONCLUSIONS: Terlipressin might contribute to obtain sustained return of spontaneous circulation in children with refractory in-hospital cardiac arrest. A randomized controlled clinical trial should be conducted to investigate the optimal drug treatment in pediatric cardiac arrest.
机译:目的:小儿心脏骤停对晚期生命支持无反应,多次肾上腺素剂量预后很差。在这种情况下,其他升压药可以改善复苏的效果。我们报告了在儿童重症监护病房心脏骤停且对即时高级生命支持和至少三剂肾上腺素剂量无反应的儿童中,特有性地给予特利加压素的经验。设计:预期的多中心注册表。地点:大学附属三级儿童医院的三个儿科重症监护室。患者:5例年龄在5个月至12岁之间的小儿科患者,其小儿重症监护室心脏骤停对包括至少三剂肾上腺素在内的高级生命支持无反应。干预措施:在标准心肺复苏中加用特利加压素(静脉注射10-20微克/千克,最多两剂)。测量和主要结果:4例患者实现了自发性循环的持续恢复,其中2例在6和12小时后被宣布死亡,其余2例在没有与心肺手术相关的后遗症且神经系统状况良好的情况下存活。结论:特利加压素可能有助于顽固性院内心脏骤停患儿获得自发性循环持续恢复。应该进行一项随机对照临床试验,以研究小儿心脏骤停的最佳药物治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号